Unit

Laboratory of Biomaterials for Immunoengineering

Laboratory

Related publications (112)

Graph Chatbot

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

An autonomous microfluidic device for identification and analysis of individual clinically-relevant mammalian cells

Fabien Louis Claude Robert Jammes

Cancer represents one of the major public health challenges worldwide, representing more than 25% of all deaths in the European Union in 2014. It affects a large and growing part of the general population, with the National Cancer Institute (NCI) estimatin ...

EPFL2021

Cytokine engineering for targeted cancer immunotherapy

Li Tang, Lucia Bonati

Cytokines are key modulators of the immune responses and represent promising therapeutics for a variety of cancers. However, successful translation of cytokine-based therapy to the clinic is limited by, among others, severe toxicities and lack of efficacy ...

2021

Immunotherapy has been used in oncology in order to awaken the immune system of the patient against cancer. Within this promising field is emerging the use of therapeutic cancer vaccines, using tumor specific antigens to stimulate dendritic cells (DCs) ex ...

EPFL2021

Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer

Hatice Altug, Alexander Mathis, George Coukos, Xiaokang Li, Yen-Cheng Liu, David Gfeller, Pedro Romero, Alexandre Harari, Amélie Cachot, Margaux Saillard, Georg Alexander Rockinger

CD4 T cells have been implicated in cancer immunity for their helper functions. Moreover, their direct cytotoxic potential has been shown in some patients with cancer. Here, by mining single-cell RNA-seq datasets, we identified CD4 T cell clusters displayi ...

2021

, , , , , , , ,

Targeting the stimulator of interferon genes (STING) pathway with cyclic dinucleotides (CDNs), the natural STING agonists, is a promising immunotherapeutic strategy for cancer. However, the clinical application of natural CDNs as therapeutics is greatly hi ...

2021

The immune checkpoint blockade-based immunotherapies are revolutionizing cancer management. Tumor-associated neutrophils (TANs) were recently highlighted to have a pivotal role in modulating the tumor microenvironment and the antitumor immune response. How ...

BMJ PUBLISHING GROUP2021

, , , ,

T cells are important for controlling ovarian cancer (OC). We previously demonstrated that combinatorial use of a personalized whole-tumor lysate-pulsed dendritic cell vaccine (OCDC), bevacizumab (Bev), and cyclophosphamide (Cy) elicited neoantigen-specifi ...

2021

, ,

The present disclosure relates to new agents useful for anti-cancer therapy such as anti-cancer adoptive T-cell transfer (ACT) immunotherapy or immune check-point blockade therapy and related compositions, uses and methods thereof. ...

2021

Delivery of STING agonists for adjuvanting subunit vaccines

Li Tang, Bing Feng, Simon Bart M. Van Herck

Adjuvant is an essential component in subunit vaccines. Many agonists of pathogen recognition receptors have been developed as potent adjuvants to optimize the immunogenicity and efficacy of vaccines. Recently discovered cyclic GMP-AMP synthase-stimulator ...

ELSEVIER2021

Targeting LRG1 boosts immunotherapy

Michele De Palma, Amanda Waite Lund

Vascular normalization therapy has the potential to facilitate drug delivery and lymphocyte infiltration in tumors. Yet, optimal targets and dosage regimens remain elusive. In this issue of Med, O’Connor et al. show that inhibition of LRG1 stabilizes the t ...

2021